Tuba N. Gide

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Tuba N. Gide, Camelia Quek, Alexander M. Menzies et al. · Cancer Cell · 2019 · 980 citations · Full text

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Imran G. House, Peter Savas, Junyun Lai et al. · Clinical Cancer Research · 2019 · 689 citations

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

Jarem Edwards, James S. Wilmott, Jason Madore et al. · Clinical Cancer Research · 2018 · 430 citations

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

Su Yin Lim, Jenny Lee, Tuba N. Gide et al. · Clinical Cancer Research · 2018 · 353 citations

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients

Hojabr Kakavand, Louise Jackett, Alexander M. Menzies et al. · Modern Pathology · 2017 · 215 citations · Full text

Cancer Immunosurveillance, Anti-pd-1 Therapy, Medicine +8